Every Form 4 that Zymeworks Inc. (ZYME) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ZYME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZYME filings page.
Zymeworks Inc. executive Mark Hollywood, EVP & Chief Operating Officer, acquired 939 shares of common stock through the company’s Employee Stock Purchase Plan. The shares were bought for $22.22 each, reflecting a 15% discount to the closing price on June 30, 2026. After this ESPP purchase, he holds 133,852 common shares directly, so the new shares represent a small addition to his existing position.
Schneider Paul R reported acquisition or exercise transactions in this Form 4 filing.
Zymeworks Inc. reported that EVP and General Counsel Paul R. Schneider received new equity compensation. On May 13, 2026, he was granted 119,000 restricted stock units, each representing one share of common stock upon vesting, and 178,000 stock options with a strike price of $24.57 per share.
The options vest 25% on the first anniversary of the grant and the remaining 75% in 36 equal monthly installments. The RSUs vest in four equal annual installments beginning on the first anniversary of the grant date. Following these awards, he holds 119,000 RSUs and 178,000 options directly.
Zymeworks Inc. reported that officer Adam Schayowitz received new equity awards as part of his compensation. On April 9, 2026, he was granted stock options for 70,000 shares of common stock at an exercise price of $27.35 per share, expiring on April 8, 2036. These options vest 25% on the first anniversary of the grant and the rest in 36 monthly installments.
He also received 47,000 restricted stock units that vest in four equal annual installments, plus up to 76,000 performance stock units. The performance units can be earned between 50% and 200% of a 38,000-unit target based on cumulative total shareholder return over a three-year period ending on January 12, 2029, subject to continued service and specific TSR goals.
Zymeworks Inc. granted equity-based compensation to EVP and Chief Business Officer Scott Platshon. He received stock options for 70,000 shares of common stock at an exercise price of $27.35 per share, expiring on April 8, 2036, which vest 25% after one year and monthly thereafter.
Platshon was also granted 47,000 restricted stock units that vest in four equal annual installments, each RSU delivering one share of common stock upon vesting. In addition, he received 76,000 performance stock units, representing the maximum number that may be earned based on cumulative total shareholder return goals over a three-year performance period ending on January 12, 2029, with 50%–200% of a 38,000-unit target earnable depending on performance.
Zymeworks Inc. reported that EVP and Chief Financial Officer Kristin Stafford received new equity compensation awards. She was granted stock options for 178,000 shares of common stock at an exercise price of $25.84 per share, expiring on April 5, 2036. These options vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Stafford also received two restricted stock unit grants. One award covers 119,000 RSUs, vesting in four equal annual installments beginning on the first anniversary of the grant date. The other covers 50,000 RSUs, vesting in three equal annual installments starting on the first anniversary. Each RSU converts into one share of common stock upon vesting, and the filing shows no open-market purchases or sales.
Zymeworks Inc. executive Mark Hollywood, EVP & Chief Operating Officer, reported equity compensation activity on January 12, 2026. One third of previously granted restricted stock units vested, converting into 17,666 shares of common stock at no cost. To cover related tax withholding and fees under a mandatory “sell to cover” provision, 6,120 shares were sold at a weighted average price of $22.6735, leaving him with 132,913 common shares held directly.
He also received new awards: stock options for 70,000 shares at a $23.16 exercise price, 47,000 new RSUs, and 66,000 performance stock units. The options vest 25% after one year and the rest monthly over three years. The RSUs vest in four equal annual installments. The PSUs can deliver up to 66,000 shares based on cumulative total shareholder return goals over a three-year period ending January 12, 2029.
Zymeworks Inc. director Brian N. Cherry reported new equity awards granted on January 12, 2026. He received a stock option for 23,000 shares of common stock at an exercise price of $23.16 per share, vesting in 36 equal monthly installments starting one month after the grant date. He also received 15,400 restricted stock units (RSUs), each representing the right to receive one share of common stock upon vesting. These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date. Both awards are reported as directly owned following the transactions.
Zymeworks Inc.'s EVP & Chief Medical Officer, Jeffrey T. L. Smith, reported the vesting of 17,666 restricted stock units (RSUs) on January 12, 2026, which converted into the same number of common shares at $0.00 per share. These RSUs were part of a grant made on January 10, 2025 that vests in three equal annual installments, with each RSU delivering one share of common stock upon vesting.
On the same date, 9,310 common shares were sold at a weighted average price of $22.6735 solely to cover tax withholding and related fees under mandatory “sell to cover” provisions, and not as a discretionary sale. After these transactions, Smith beneficially owned 26,708 common shares and 35,334 RSUs, all reported as directly held.
Zymeworks Inc. director Gregory Austin Ciongoli reported new equity awards on a Form 4. On January 12, 2026, he was granted stock options covering 11,500 shares of common stock at an exercise price of $23.16 per share. These options vest on January 12, 2027 and expire on January 11, 2036.
He also received 7,700 restricted stock units (RSUs) on the same date. Each RSU represents the right to receive one share of common stock upon vesting, and these RSUs vest on January 12, 2027. All reported derivative holdings are shown as directly owned, and the filing reflects awards being acquired rather than any sale of shares.
Zymeworks Inc. director Kelvin Neu reported new equity awards in a Form 4 dated January 12, 2026. He was granted 11,500 stock options with an exercise price of $23.16 per share and 7,700 restricted stock units (RSUs), all held as direct beneficial ownership.
The stock options and RSUs both vest on January 12, 2027. Each RSU gives the right, upon vesting, to receive one share of Zymeworks common stock. These transactions reflect equity compensation to a board member rather than open-market buying or selling.
Zymeworks Inc. reported that director Robert E. Landry received new equity awards. On January 12, 2026, he was granted stock options to buy 11,500 shares of common stock at an exercise price of $23.16 per share. These options vest on January 12, 2027 and expire on January 11, 2036, leaving him with 11,500 derivative securities beneficially owned after the grant.
On the same date, he was also granted 7,700 restricted stock units (RSUs), each representing the contingent right to receive one share of common stock upon vesting. These RSUs vest on January 12, 2027, and 7,700 derivative securities are shown as beneficially owned directly following the transactions.
Zymeworks Inc. director Alessandra Cesano received new equity awards, including stock options and restricted stock units. On January 12, 2026, she was granted stock options covering 11,500 shares of common stock and 7,700 restricted stock units. The footnotes state that the options vest on January 12, 2027 and that each RSU converts into one share of common stock upon vesting, with the RSUs also vesting on January 12, 2027. These awards are reported as directly owned following the transactions.
Zymeworks Inc. director Carlos Campoy reported new equity awards. On January 12, 2026 he received stock options covering 11,500 shares of common stock at an exercise price of $23.16 per share, which vest on January 12, 2027. He also received 7,700 restricted stock units, each representing one share of common stock, with the RSUs vesting on January 12, 2027. Following these awards, he directly holds 11,500 stock options and 7,700 RSUs in the company.
Zymeworks Inc. director Susan Mahony reported new equity awards. On January 12, 2026, she was granted stock options covering 11,500 shares of Zymeworks common stock with an exercise price of $23.16 per share. These options vest on January 12, 2027 and are scheduled to expire on January 11, 2036.
She was also granted 7,700 restricted stock units (RSUs) on the same date. Each RSU represents the right to receive one share of common stock upon vesting, and all 7,700 RSUs vest on January 12, 2027. Both the options and RSUs are reported as directly owned by Mahony.
Zymeworks Inc. Chief Scientific Officer Paul Andrew Moore reported multiple equity transactions on January 12, 2026. One third of a prior restricted stock unit (RSU) grant vested, resulting in 17,666 shares of common stock, and 9,560 shares were sold at a weighted average price of $22.6735 solely to cover tax withholding and related fees under a mandatory sell-to-cover provision. After these transactions, he directly held 48,497 shares of common stock.
On the same date, Moore received new equity awards, including 70,000 stock options with a $23.16 exercise price that vest 25% after one year and the rest in 36 monthly installments. He was also granted 47,000 RSUs vesting in four equal annual installments and 66,000 performance stock units, representing the maximum shares that may be earned based on total shareholder return goals over a three-year period ending January 12, 2029, subject to continued service.
Zymeworks Inc. Chair and CEO Kenneth Galbraith reported equity award activity and a tax-related share sale. On January 12, 2026, 64,000 restricted stock units vested and were settled into common shares at $0.00, and 30,424 common shares were sold at a weighted average price of $22.6735 solely to cover tax withholding and fees under mandatory “sell to cover” provisions. After these transactions, he directly held 226,842 common shares.
On the same date, he received new equity awards: a stock option for 216,000 shares at an exercise price of $23.16 expiring on January 11, 2036, which vests 25% after one year and monthly thereafter; a new RSU grant of 144,000 shares vesting in four equal annual installments; and performance stock units covering up to 222,000 shares tied to total shareholder return goals over a three-year period ending January 12, 2029, with 50%–200% of a 111,000-target range potentially earned.
Zymeworks Inc. executive Patterson Leone, EVP and Chief Business & Financial Officer, reported buying common stock through the company’s employee stock purchase plan. On January 6, 2026, Leone acquired 459 shares of common stock at a price of $10.55 per share, bringing reported beneficial ownership to 459 shares held directly. The filing notes these shares were purchased under Zymeworks’ Amended and Restated Employee Stock Purchase Plan for the purchase period from July 1, 2025 through December 31, 2025, at a price equal to 85% of the closing price of the stock on July 1, 2025.